Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Amortizatization of Intangibles: 2014-2024

Historic Amortizatization of Intangibles for Coherus Oncology (CHRS) over the last 11 years, with Dec 2024 value amounting to $4.2 million.

  • Coherus Oncology's Amortizatization of Intangibles fell 153.50% to -$428,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $2.4 million, marking a year-over-year decrease of 62.57%. This contributed to the annual value of $4.2 million for FY2024, which is 72.79% up from last year.
  • As of FY2024, Coherus Oncology's Amortizatization of Intangibles stood at $4.2 million, which was up 72.79% from $2.4 million recorded in FY2023.
  • In the past 5 years, Coherus Oncology's Amortizatization of Intangibles registered a high of $6.4 million during FY2022, and its lowest value of $2.4 million during FY2023.
  • In the last 3 years, Coherus Oncology's Amortizatization of Intangibles had a median value of $4.2 million in 2024 and averaged $4.3 million.
  • In the last 5 years, Coherus Oncology's Amortizatization of Intangibles slumped by 62.57% in 2023 and then skyrocketed by 72.79% in 2024.
  • Over the past 5 years, Coherus Oncology's Amortizatization of Intangibles (Yearly) stood at $3.5 million in 2020, then grew by 22.29% to $4.3 million in 2021, then surged by 51.07% to $6.4 million in 2022, then tumbled by 62.57% to $2.4 million in 2023, then skyrocketed by 72.79% to $4.2 million in 2024.